Crestor - magic bullet, or more trouble than it’s worth?
This article was originally published in Scrip
Executive Summary
At first sight, the FDA advisory panel endorsement of wider indications for AstraZeneca’s HMG Co-A reductase inhibitor Crestor (rosuvastatin; scripnews.com, 16 December 2009) looks like good news both for the company and for patients.